- Home
- CLLS vs LUNG Comparison
CLLS vs LUNG Comparison
Compare CLLS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- LUNG
- Stock Information
- Founded
- CLLS 1999
- LUNG 1995
- Country
- CLLS France
- LUNG United States
- Employees
- CLLS N/A
- LUNG N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- CLLS Health Care
- LUNG Health Care
- Exchange
- CLLS Nasdaq
- LUNG Nasdaq
- Market Cap
- CLLS 299.0M
- LUNG 65.6M
- IPO Year
- CLLS 2007
- LUNG 2020
- Fundamental
- Price
- CLLS $3.12
- LUNG $1.60
- Analyst Decision
- CLLS Buy
- LUNG Buy
- Analyst Count
- CLLS 1
- LUNG 7
- Target Price
- CLLS $4.00
- LUNG $7.66
- AVG Volume (30 Days)
- CLLS 77.9K
- LUNG 543.0K
- Earning Date
- CLLS 11-03-2025
- LUNG 10-29-2025
- Dividend Yield
- CLLS N/A
- LUNG N/A
- EPS Growth
- CLLS N/A
- LUNG N/A
- EPS
- CLLS N/A
- LUNG N/A
- Revenue
- CLLS $63,438,000.00
- LUNG $90,549,000.00
- Revenue This Year
- CLLS N/A
- LUNG $10.30
- Revenue Next Year
- CLLS $66.76
- LUNG $14.72
- P/E Ratio
- CLLS N/A
- LUNG N/A
- Revenue Growth
- CLLS 223.09
- LUNG 18.24
- 52 Week Low
- CLLS $1.10
- LUNG $1.47
- 52 Week High
- CLLS $3.35
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- CLLS 64.92
- LUNG 39.14
- Support Level
- CLLS $2.88
- LUNG $1.60
- Resistance Level
- CLLS $3.35
- LUNG $1.76
- Average True Range (ATR)
- CLLS 0.17
- LUNG 0.13
- MACD
- CLLS 0.02
- LUNG 0.03
- Stochastic Oscillator
- CLLS 71.76
- LUNG 6.42
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.